基于Hcy、NT-proBNP及FAR水平构建川崎病冠脉病变预警模型及早期分层药物治疗策略的临床研究
Clinical Study on the Construction of an Early Warning Model and Early Stratified Drug Therapy Strategies for Coronary Artery Lesions in Kawasaki Disease Based on Hcy, NT-proBNP, and FAR Levels
DOI: 10.12677/jcpm.2026.54226, PDF,   
作者: 胡若卉:内蒙古科技大学包头医学院研究生学院,内蒙古 包头;内蒙古包头市中心医院儿科,内蒙古 包头;宁丹妮:内蒙古医科大学包头临床医学院,内蒙古 包头;陈 强*:内蒙古包头市中心医院儿科,内蒙古 包头
关键词: 川崎病冠状动脉病变同型半胱氨酸N末端脑钠肽前体纤维蛋白原/白蛋白比值 Kawasaki Disease Coronary Artery Lesions Homocysteine N-Terminal Pro-Brain Natriuretic Peptide Fibrinogen-to-Albumin Ratio
摘要: 目的:探讨血清同型半胱氨酸(Hcy)、N末端脑钠肽前体(NT-proBNP)及纤维蛋白原/白蛋白比值(FAR)对儿童川崎病(KD)冠脉病变(CAL)的预测价值,并构建联合预测模型,为CAL的早期风险评估提供参考。方法:回顾性分析60例KD患儿(CAL组26例,非CAL组34例)临床资料。通过多因素Logistic回归筛选CAL独立危险因素并构建预测模型,利用ROC曲线评价其诊断效能,并基于模型风险评分(RS)拟定分层干预策略。结果:1) CAL组血清Hcy、NT-proBNP及FAR水平均显著高于非CAL组(均P < 0.001);相关性分析显示,Hcy (r = 0.685)、NT-proBNP (r = 0.668)及FAR (r = 0.693)与冠脉Z值均呈显著正相关(均P < 0.05)。2) 年龄(OR = 0.218, P = 0.002)与Hcy (OR = 2.457, P = 0.020)是KD合并CAL的独立危险因素。3) 构建年龄、血清Hcy、NT-proBNP及FAR的多维度联合预警模型,其AUC达0.909,以RS ≥ 0.515为截断值时灵敏度为88.50%,特异度为91.20%,提示该模型具有较好的风险区分能力。结论:年龄和Hcy是KD患儿发生CAL的独立影响因素。基于年龄、Hcy、NT-proBNP及FAR构建的联合预测模型具有较好的预测效能,可为CAL早期风险评估提供参考。
Abstract: Objective: To investigate the predictive value of serum homocysteine (Hcy), N-terminal pro-brain natriuretic peptide (NT-proBNP), and fibrinogen-to-albumin ratio (FAR) for coronary artery lesions (CAL) in children with Kawasaki disease (KD), and to develop a quantitative stratified pharmacological intervention pathway based on the combined model. Methods: Clinical data from 60 children with KD (26 in the CAL group and 34 in the non-CAL group) were retrospectively analyzed. Multivariate logistic regression analysis was performed to identify independent risk factors for CAL and to construct a predictive model. The performance of the model was evaluated using receiver operating characteristic (ROC) curves. Subsequently, a clinical stratified medication protocol was developed based on the model-derived risk scores. Results: 1) The serum levels of Hcy, NT-proBNP, and FAR in the CAL group were significantly higher than those in the non-CAL group (all P < 0.001). Correlation analysis revealed that Hcy (r = 0.685), NT-proBNP (r = 0.668), and FAR (r = 0.693) were all significantly and positively correlated with coronary Z-scores (all P < 0.05). 2) Multivariate logistic regression analysis identified that age (OR = 0.218, P = 0.002) and Hcy (OR = 2.457, P = 0.02) were independent risk factors for CAL in children with KD. 3) A combined prediction model based on age, serum Hcy, NT-proBNP, and FAR was constructed. The model yielded an AUC of 0.909. At an RS cutoff value of 0.515, the sensitivity and specificity were 88.50% and 91.20%, respectively, suggesting that the model may have good discriminatory performance for the early risk assessment of CAL. Conclusion: Age and Hcy were independent factors associated with the development of CAL in children with KD. The combined prediction model based on age, Hcy, NT-proBNP, and FAR showed good predictive performance and may serve as a preliminary tool for the early risk assessment of CAL.
文章引用:胡若卉, 宁丹妮, 陈强. 基于Hcy、NT-proBNP及FAR水平构建川崎病冠脉病变预警模型及早期分层药物治疗策略的临床研究[J]. 临床个性化医学, 2026, 5(4): 70-79. https://doi.org/10.12677/jcpm.2026.54226

参考文献

[1] Kawasaki, T. (1967) Acute Febrile Mucocutaneous Syndrome with Lymphoid Involvement with Specific Desquamation of the Fingers and Toes in Children. Arerugi, 16, 178-222.
[2] Mccrindle, B.W., Rowley, A.H., Newburger, J.W., et al. (2017) Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals from the American Heart Association. Circulation, 135, e927-e999.
[3] Houska, N., Albertz, M. and Ing, R.J. (2025) Update on Diagnosis and Management of Kawasaki Disease: A Scientific Statement from the American Heart Association. Journal of Cardiothoracic and Vascular Anesthesia, 39, 1103-1105.
https://doi.org/10.1053/j.jvca.2025.02.007
[4] Day-Lewis, M., Son, M.B.F. and Lo, M.S. (2024) Kawasaki Disease: Contemporary Perspectives. The Lancet Child & Adolescent Health, 8, 781-792.
https://doi.org/10.1016/s2352-4642(24)00169-x
[5] Pilania, R.K., Tremoulet, A.H., Prinja, S., Dahdah, N. and Singh, S. (2025) Kawasaki Disease: The Most Common Cause of Acquired Heart Disease among Children Globally. Cardiology in the Young, 35, 441-443.
https://doi.org/10.1017/s1047951125000459
[6] Agarwal, S. and Agrawal, D.K. (2017) Kawasaki Disease: Etiopathogenesis and Novel Treatment Strategies. Expert Review of Clinical Immunology, 13, 247-258.
https://doi.org/10.1080/1744666x.2017.1232165
[7] Kang, C.R., Lee, J.S. and Choe, Y.J. (2025) Global Incidence of Kawasaki Disease: A Systematic Review. Cardiology in the Young, 35, 1028-1039.
[8] Chaudhuri, M., Tomar, M. and Chattopadhyay, A. (2025) Imaging in Kawasaki Disease: The Past, Present, and Future. Journal of the Indian Academy of Echocardiography & Cardiovascular Imaging, 9, 179-188.
https://doi.org/10.4103/jiae.jiae_63_25
[9] Hsu, W.F., Huang, Y.H., Tsai, F.J., et al. (2025) Epidemiological Trends and Healthcare Burden of Kawasaki Disease in Children under 5 Years in Taiwan Region. Scientific Reports, 15, Article No. 40622.
https://doi.org/10.1038/s41598-025-24444-3
[10] Park, Y.W. (2008) Epidemiology of Kawasaki Disease in Korea. Korean Journal of Pediatrics, 51, 452-456.
[11] Shih, W.L., Huang, L.M., Wu, M.H., et al. (2024) Secular Trend of Kawasaki Disease and Its Correlation with Viral Activity in Taiwan Region: A Nationwide Population-Based Study. BMC Public Health, 24, Article No. 1591.
https://doi.org/10.1186/s12889-024-19066-9
[12] Goyal, T., Sharma, S., Pilania, R.K., Jawallia, K., Chawla, S., Sharma, M., et al. (2025) Genetic Landscape of Kawasaki Disease: An Update. Lymphatics, 3, Article 21.
https://doi.org/10.3390/lymphatics3030021
[13] Gorelik, M., Chung, S.A., Ardalan, K., Binstadt, B.A., Friedman, K., Hayward, K., et al. (2022) 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease. Arthritis Care & Research, 74, 538-548.
https://doi.org/10.1002/acr.24838
[14] Shiono, Y., Takahata, M., Ino, Y., Tanimoto, T., Kakimoto, N., Suenaga, T., et al. (2024) Pathological Alterations of Coronary Arteries Late after Kawasaki Disease: An Optical Coherence Tomography Study. JACC: Advances, 3, Article 100937.
https://doi.org/10.1016/j.jacadv.2024.100937
[15] Mat Bah, M.N., Alias, E.Y., Sapian, M.H. and Abdullah, N. (2022) Delayed Diagnosis of Kawasaki Disease in Malaysia: Who Is at Risk and What Is the Outcome. Pediatrics International, 64, e15162.
https://doi.org/10.1111/ped.15162
[16] Liu, L., Chen, R., Wang, H., Yu, H., Ai, Z. and Zhang, X. (2025) Nutrition-Associated Biomarkers in Predicting Intravenous Immunoglobulin Resistance and Coronary Artery Lesions in Kawasaki Disease: A Systematic Review and Meta-Analysis. Food Science & Nutrition, 13, e4647.
https://doi.org/10.1002/fsn3.4647
[17] Jakubowski, H. and Witucki, Ł. (2025) Homocysteine Metabolites, Endothelial Dysfunction, and Cardiovascular Disease. International Journal of Molecular Sciences, 26, Article 746.
https://doi.org/10.3390/ijms26020746
[18] 郭永宏, 杨艳峰, 高放, 等. 同型半胱氨酸对人冠状动脉内皮细胞中组织蛋白酶V和炎症因子表达的影响机制[J]. 实用临床医药杂志, 2022, 26(3): 39-43.
[19] 孙欣娜, 于泊, 杨青, 等. 川崎病CK-MB、NT-proBNP、H-FABP和冠状动脉Z值的变化及其与冠脉病变的相关性研究[J]. 临床和实验医学杂志, 2022, 21(13): 1384-1387.
[20] 李明康. 非ST段抬高型急性冠脉综合征患者纤维蛋白原/白蛋白比值与冠脉病变程度及预后的相关性研究[D]: [硕士学位论文]. 南京: 东南大学, 2021.
[21] 黄玉娟, 李夙凌, 田园, 等. 中国儿童川崎病诊疗循证指南(2023年) [J]. 中国当代儿科杂志, 2023, 25(12): 1198-1210.
[22] Kim, S.H. (2022) Diagnosis of Coronary Artery Abnormalities in Kawasaki Disease: Recent Guidelines and Z Score Systems. Clinical and Experimental Pediatrics, 65, 430-438.
https://doi.org/10.3345/cep.2021.01459
[23] Dallaire, F. and Dahdah, N. (2011) New Equations and a Critical Appraisal of Coronary Artery Z Scores in Healthy Children. Journal of the American Society of Echocardiography, 24, 60-74.
https://doi.org/10.1016/j.echo.2010.10.004
[24] Gerling, S., Hörl, M., Geis, T., Zant, R., Dechant, M., Melter, M., et al. (2022) Coronary Artery Z-Scores in Febrile Children with Suspected Kawasaki’s Disease—The Value of Serial Echocardiography. The Thoracic and Cardiovascular Surgeon, 70, e1-e6.
https://doi.org/10.1055/s-0042-1747674
[25] 何方园, 何学华, 袁勇华, 等. 川崎病急性期血脂与年龄, 冠状动脉病变及严重程度的关系[J]. 临床儿科杂志, 2023, 41(6): 455-458.
[26] Choueiter, N.F., Jone, P. and Harahsheh, A.S. (2025) Comparing the 2024 and 2017 Kawasaki Disease Statements from the American Heart Association. Pediatrics, 156, e2024069800.
https://doi.org/10.1542/peds.2024-069800
[27] Fukazawa, R., Kobayashi, J., Ayusawa, M., Hamada, H., Miura, M., Mitani, Y., et al. (2020) JCS/JSCS 2020 Guideline on Diagnosis and Management of Cardiovascular Sequelae in Kawasaki Disease. Circulation Journal, 84, 1348-1407.
https://doi.org/10.1253/circj.cj-19-1094
[28] Jone, P.N., Tremoulet, A., Choueiter, N., et al. (2024) Update on Diagnosis and Management of Kawasaki Disease: A Scientific Statement from the American Heart Association. Circulation, 150, e481-e500.
https://doi.org/10.1161/cir.0000000000001295
[29] de Graeff, N., Groot, N., Ozen, S., Eleftheriou, D., Avcin, T., Bader-Meunier, B., et al. (2019) European Consensus-Based Recommendations for the Diagnosis and Treatment of Kawasaki Disease—The SHARE Initiative. Rheumatology, 58, 672-682.
https://doi.org/10.1093/rheumatology/key344
[30] McCaddon, A. and Miller, J.W. (2023) Homocysteine—A Retrospective and Prospective Appraisal. Frontiers in Nutrition, 10, Article 1179807.
https://doi.org/10.3389/fnut.2023.1179807
[31] Suda, K., Iemura, M., Nishiono, H., Teramachi, Y., Koteda, Y., Kishimoto, S., et al. (2011) Long-Term Prognosis of Patients with Kawasaki Disease Complicated by Giant Coronary Aneurysms: A Single-Institution Experience. Circulation, 123, 1836-1842.
https://doi.org/10.1161/circulationaha.110.978213
[32] Echouffo‐Tcheugui, J.B., Zhang, S., Daya, N., McEvoy, J.W., Tang, O., Juraschek, S.P., et al. (2023) NT‐proBNP and All‐Cause and Cardiovascular Mortality in US Adults: A Prospective Cohort Study. Journal of the American Heart Association, 12, e029110.
https://doi.org/10.1161/jaha.122.029110
[33] Li, D., Zhang, W.J., Feng, H.Q., et al. (2025) Elevated Levels of NT-proBNP, Interferon-γ and Tumor Necrosis Factor-α Are Associated with Coronary Artery Injury in Children with Severe Kawasaki Disease. American Journal of Translational Research, 17, 3683-3690.
https://doi.org/10.62347/ajmb5384
[34] 孟欣, 白红艳, 李茜, 等. 纤维蛋白原/白蛋白比值血小板参数与冠状动脉病变程度相关性研究[J]. 河北医学, 2025, 31(8): 1364-1369.
[35] 杨安妮, 厉腊梅, 周桐, 等. 纤维蛋白原/白蛋白比值与早发冠心病的相关性研究[J]. 心血管病学进展, 2025, 46(9): 850-854.